Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

l, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Isch
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013  Aribex, Inc., manufacturer of the newly released ... new color option, black with gray trim, of the ... markets. The popular white with light blue trim Pro ... be available and both models can be purchased from ... http://photos.prnewswire.com/prnh/20130522/CL19573 ) "Dental offices are adding ...
(Date:5/22/2013)... May 22, 2013 Attorney Advertising -- Bronstein, ... on behalf of purchasers of the securities of ... AMAG -News).  The investigation focuses on whether the ... On May 22, 2013, Shares of ... after the company announced in regulatory filing that ...
(Date:5/22/2013)... and CAESAREA, Israel , May ... , New clinical data presented from the DEFLECT-I study ... Device reduces brain lesion volume during TAVR (Transcatheter Aortic ... Keystone Heart Scientific Advisory Board announces consensus on ... rising regarding the importance and need for cerebral protection ...
Breaking Medicine Technology:Aribex Unveils New Color of NOMAD Pro 2 2Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4
... study published today in the,journal Current Medical ... superior to Cymbalta®,(duloxetine) in the acute treatment ... was at least as efficacious in,long-term treatment. ... reuptake inhibitor - ASRI) to duloxetine (a,serotonin ...
... - Both co-primary endpoints, Wake After Sleep Onset and ... Sleep, were met at both doses - Evotec to ... 10am EST) today , HAMBURG, Germany | OXFORD, England, ... today positive top-line,results from its first phase II clinical ...
Cached Medicine Technology:Cipralex demonstrates superiority to duloxetine for acute treatment,of depression in new study 2Cipralex demonstrates superiority to duloxetine for acute treatment,of depression in new study 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4
(Date:5/23/2013)... Platinum Supplemental Insurance recently promoted Mary ... started her Platinum sales career in 2011. Her commitment ... of sales representatives selling Platinum products. , Platinum markets ... of rural communities. Satterlee is in charge of a ... help farmers prepare for the future in the event ...
(Date:5/23/2013)... Francisco, CA (PRWEB) May 23, 2013 ... safety outreach program being tackled by the Safe Passage ... second Fullpower personal safety workshop for women ... and teaches personal safety skills programs for people of ... telling us their experiences with street harassment for years,” ...
(Date:5/23/2013)... May 23, 2013 Fresh Healthy Vending ... machines stocked with healthy food and drinks in locations ... company’s in-house, full-service marketing and advertising department has a ... the media for their franchisees, and to promote the ... been featured in many leading publications and TV networks ...
(Date:5/23/2013)... 2013 Registered Dietitian and Founder of ... today on Tatalou.com offering helpful tips for travelers who ... titled “ How to Stay Healthy While Traveling ,” ... sanitizer, when it’s safe to drink the water when ... importance of staying hydrated and how taking health supplements ...
(Date:5/23/2013)... May 23, 2013 Teen birth rates declined ... to new data released today by the CDC’s ... teen birth rate dropped at least 15% in 48 states ... There were also dramatic declines among all racial/ethnic groups as ...     Birth rates declined 40% or more for Hispanic teens in ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Promotes Mary Satterlee to Sales Team Leader 2Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 2Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 3Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 4Health News:Fresh Healthy Vending Receives Recent National and Local Media Focus 2Health News:How to Stay Healthy While Traveling 2
... Bradford, from Oswestry, a patient with breast cancer in England ... are given free drug treatment// at a hospital. Local health ... the Shropshire Primary Care Trust. The patients in Shropshire have ... protest at the hospital on Monday. ,North Shropshire ...
... London, the cause of autism may now be explained due t ... not interacting well with other people. Weak links between brain areas ... situations as well as other people. ,The study ... an Autism Spectrum Disorder (ASD) while the other 16 did not. ...
... NHS trust failed to adequately supervise two doctors. Amit ... Hospital. It led to the death of the patient ... surgery. He suffered toxic shock syndrome. The hospital ... house officers. ,At a sentencing hearing at ...
... According to a new study of women with early stage, ... disease have been identified that may influence how patients are ... patients from 1988 to 2002 was reviewed by Cancer Research ... are risk factors for invasive disease and the pattern of ...
... Office (NHSO) has found that women aged above 35 are ... should annually undergo a Pap smear test for early detection ... is the most common type of cancer among women. ... scheme, has provided Pap smear services to 1.5 million women ...
... heart's largest artery, the aorta. Studies were going on to ... Johns Hopkins University// have successfully come up with the treatment. ... in recent studies for treating the genetic disorder. The ... appears to prevent the weakening of the heart's largest artery, ...
Cached Medicine News:Health News:Cancer Patients Protest For Free Drug Treatment 2Health News:Lack Of Communication Between Brain Areas Can Cause Autism 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: